James Amatruda, MD, PhD

Professor of Pediatrics

Image of James Amatruda, MD, PhD
Is this your profile? Click to edit

Overview

James F. Amatruda, MD, PhD is Chief of the Division of Hematology-Oncology and Director of the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles; and Professor of Pediatrics and Medicine at the Keck School of Medicine of the University of Southern California. He received his Bachelor’s degree in Biochemical Sciences from Harvard University and his MD,PhD from Washington University School of Medicine. He did internship and residency training in Internal Medicine at the Brigham and Women’s Hospital in Boston, MA, followed by fellowship training in Medical Oncology at Dana-Farber/Partners Cancer Care in Boston, MA. He was a Postdoctoral Fellow in the laboratory of Dr. Leonard Zon at Boston Children’s Hospital, Harvard Medical School. From 2005-2019, Dr. Amatruda was on the faculty of UT Southwestern Medical Center in Dallas, TX.

Dr. Amatruda is a physician-scientist with a primary research and clinical focus on solid tumors of childhood including sarcomas, germ cell tumors and Wilms tumor. His lab has developed zebrafish models of genetic subtypes of pediatric solid tumors to better define their biology and to use that knowledge to identify and validate novel approaches for improved therapies. He has had long-standing leadership positions in the Children’s Oncology Group; serving as Chair for the Germ Cell Tumor Biology Committee and the Rare Tumors Biology Committee. He also serves as a member of the COG Solid Malignancies Integrated Translational Science Center Steering Committee, and on the Scientific Advisory Boards of the William Guy Forbeck Foundation, the Pablove Foundation, Curing Kids Cancer and the Sam Day Foundation.

Education and Training

  • Harvard University, Cambridge, MA — A.B. — 05/1986 — Biochemical Sciences
  • Washington University, St. Louis, MO — M.D. — 05/1993 — Medicine
  • Washington University, St. Louis, MO — Ph.D. — 05/1993 — Cell Biology
  • Brigham and Women's Hospital, Boston, MA — 06/1996 — Internal Medicine
  • Dana-Farber/Partners Cancer Care, Boston, MA — 06/1999 — Medical Oncology

Research Keywords

  • Childhood cancer
  • Sarcoma
  • Ewing sarcoma
  • Zebrafish models
  • Germ Cell Tumor
  • Wilms tumor
  • microRNA
  • Rhabdomyosarcoma

Publications

  • Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range. Res Sq. 2023 Mar 21.. View in PubMed
  • Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors. NPJ Precis Oncol. 2023 Feb 20; 7(1):21.. View in PubMed
  • WILMS TUMOR MUTATIONAL SUBCLASSES CONVERGE TO DRIVE CCND2 OVEREXPRESSION. medRxiv. 2023 Feb 02.. View in PubMed
  • VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis. Cell Rep. 2023 01 31; 42(1):112013.. View in PubMed
  • Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection. Andrology. 2023 05; 11(4):634-640.. View in PubMed
  • Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. Br J Cancer. 2022 11; 127(9):1577-1583.. View in PubMed
  • Small round cell sarcomas. Nat Rev Dis Primers. 2022 10 06; 8(1):66.. View in PubMed
  • In vivo 3D profiling of site-specific human cancer cell morphotypes in zebrafish. J Cell Biol. 2022 11 07; 221(11).. View in PubMed
  • Response to commentary re: Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled post hoc analysis of trials from the Children’s oncology group. J Pediatr Urol. 2022 08; 18(4):513-514.. View in PubMed
  • Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled post hoc analysis of trials from the Children’s Oncology Group. J Pediatr Urol. 2022 08; 18(4):505-511.. View in PubMed